Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fusion AntibodiesLSE:FAB 24 3-Year EBITDA Growth Rate is 8.20% as of Sep. 2025. GuruFocus rates LSE:FAB with a GF Score™ of 24/100 and a GF Value™ of £0.04 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,127 Biotechnology companies, Fusion Antibodies ranks worse than 57.59% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 8.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -6.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of Fusion Antibodies was 22.90% per year. The lowest was -115.40% per year. And the median was -6.30% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Fusion Antibodies 3-Year EBITDA Growth Rate Related Terms
LSE:FAB vs VRTX, REGN, MRNA: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Fusion Antibodies's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fusion Antibodies 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fusion Antibodies's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Fusion Antibodies's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 8.20% mean?
Fusion Antibodies (LSE:FAB) has a 3-Year EBITDA Growth Rate of 8.20% as of Sep. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Fusion Antibodies and its competitors. According to the industry distribution chart, Fusion Antibodies ranks #649 out of 1127 companies in the Biotechnology industry, placing it in the top 57.6%.
Is Fusion Antibodies' 3-Year EBITDA Growth Rate too high?
Fusion Antibodies' current 3-Year EBITDA Growth Rate is 8.20%. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.60. Fusion Antibodies' value of 8.20% is 43.8% below this industry median. Based on the distribution chart, Fusion Antibodies ranks #649 out of 1127 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Fusion Antibodies has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fusion Antibodies' 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Fusion Antibodies ranks #649 out of 1127 companies for 3-Year EBITDA Growth Rate. This places Fusion Antibodies in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.60. Fusion Antibodies' value of 8.20% is 43.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.60, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fusion Antibodies's current 3-Year EBITDA Growth Rate of 8.20% is 43.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Fusion Antibodies and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fusion Antibodies's current 3-Year EBITDA Growth Rate is 8.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fusion Antibodies stock overvalued right now?
Based on GuruFocus' analysis, Fusion Antibodies (LSE:FAB) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.04, compared to a current price of £0.12 — trading 187.5% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 8.20% and 43.8% below the Biotechnology industry median of 14.60. Fusion Antibodies' overall GF Score™ is 24/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Fusion Antibodies (LSE:FAB), the current 3-Year EBITDA Growth Rate is 8.20% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fusion Antibodies (LSE:FAB) Overvalued in 2026?
Based on GuruFocus' analysis, Fusion Antibodies stock appears to be overvalued.
The current stock price of £0.12 is trading 187.5% above its estimated GF Value™ of £0.04.
GuruFocus considers Fusion Antibodies to be Significantly Overvalued.
Key valuation signals for LSE:FAB:
3-Year EBITDA Growth Rate: 8.20%
GF Value™: £0.04 vs. price of £0.12 (187.5% above fair value)
Industry Position: 43.8% below the Biotechnology median (#649 of 1127)
No single metric tells the full story. See the LSE:FAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fusion Antibodies PLC is a Contract Research Organisation (CRO) providing antibody identification, engineering, and expression services for the discovery and development of antibodies for human and veterinary therapeutics, as well as for diagnostics. Its customers are pharmaceutical, biotech, veterinary, diagnostic, and life science research companies. The company's three core service areas include: Discovery (identification, screening, and sequencing of novel antibodies); Engineering (optimising the performance of antibodies); and Supply (production and purification of antibodies for further development). Geographically company generates the majority of its revenue from North America and the Rest of the World, followed by the United Kingdom and the Rest of Europe.
24GF Score
Get the complete analysis for LSE:FAB
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:FAB has been successfully added to your 
